# デ・ウエスタン・セラピテクス研究所（4576） FY2017 Q1 四半期報告書

Source: Komori (komori.app) — https://komori.app/company/4576/filing/2017-q1
提出日: 2017-05-15
対象期間: 2017-01-01 〜 2017-03-31
企業ページ: https://komori.app/company/4576
原本（EDINET）: https://disclosure2dl.edinet-fsa.go.jp/searchdocument/pdf/S100A783.pdf

## 事業

De Western Therapeutics Institute is a drug discovery-focused company. Its primary business is exploring, developing, and licensing drug candidates and forming partnerships to monetize. For the Q1 FY2027 consolidated cumulative period, revenue was 28,972 thousand yen (down 58.7% YoY), including Granatech royalties. In-house product Granatech (eye drop solution 0.4%) has been launched domestically via license-out partner Kowa Company, with favorable sales status. Domestic collaborations include WP-1303 (H-1129) with Wakame Pharmaceutical, with a successful Phase I domestic trial completed in March and Phase II preparations underway. In February, a contract to transfer the BBG250-containing ophthalmic surgical adjunct business to Helios was signed, with ongoing post-transfer management and development provisions. An option agreement granting rights for global patent licenses outside Japan is included. Through these major contracts and the business transfer, the company aims to expand its pipeline and business scope. The quarterly consolidated financial statements for this quarter have been prepared, and disclosure is limited to a single segment (drug discovery business).

## 数字

- 研究開発費: 1億円

## 有価証券報告書にだけ載る項目

- 大株主: 保有比率と、その変動。
- 役員: 取締役の氏名、在任年数、独立性。
- 設備の状況: 拠点、帳簿価額、敷地面積。
- 沿革: 沿革と中期目標。